- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06195839
Building Engagement Using Financial Incentives Trial - Hypertension (BENEFIT-H)
The goal of this pilot clinical trial is to determine feasibility and explore whether immediate versus delayed patient financial incentives improve patient engagement with self-monitoring of blood pressure in patients with uncontrolled hypertension at Louisiana federally qualified health centers (FQHCs). The main questions it aims to answer are:
- Do patients randomized to receive financial incentives on a weekly basis during the study (immediate) have better adherence to blood pressure self-monitoring compared to patients randomized to receive financial incentives at the end of the study (delayed)?
- Do patients randomized to immediate financial incentives have better blood pressure control compared to patients randomized to delayed incentives?
Participants will:
- attend a baseline visit to measure blood pressure, respond to a baseline survey, and receive remote patient monitoring devices and instructions to take home with them (home blood pressure monitor, wrist-worn sensor to track sleep activity, and associated apps)
- receive a random allocation to one of two groups: control condition (receive cash incentives at the end of the study for measuring blood pressure as instructed) or intervention condition (receive weekly cash incentives throughout the study for measuring blood pressure as instructed)
- use remote patient monitoring devices during a two month study period, receive weekly reports on adherence to blood pressure monitoring, and receive weekly financial incentives (intervention condition only)
- attend one follow-up visit at 2 months to measure their blood pressure, complete a follow-up survey, return the remote patient monitoring devices, and receive financial incentives for blood pressure monitoring (control condition only)
Researchers will compare the immediate and delayed incentive groups to see if there are differences in blood pressure monitoring adherence rates and blood pressure control.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Louisiana
-
Bastrop, Louisiana, United States, 71220
- CommuniHealth Services
-
Shreveport, Louisiana, United States, 71107
- David Raines Community Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥40 years
- receive care at a participating FQHC
- taking blood pressure medication
- uncontrolled blood pressure at most recent clinic visit (systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥80 mm Hg)
- ability to understand and speak English
- able to access a smartphone
Exclusion Criteria:
- currently participating in another clinical trial or research study on blood pressure, medication-taking, or sleep
- unable or unwilling to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Immediate Financial Incentives for BP monitoring
|
Participants will be given a home blood pressure machine and instructed to take their blood pressure twice/day (once in the morning and once at night) for the duration of the 2-month study.
Blood pressure values will be immediately available in their patient-facing portal accessible via smartphone app, and patients will receive weekly feedback reports on their adherence to the home blood pressure monitoring protocol.
Patients' blood pressure values will also be accessible to their clinical care team via an administrator portal, which will alert clinicians of any values above or below pre-specified clinical thresholds.
As part of self-monitoring of hypertension-related factors, the blood pressure monitoring patient-facing app will also prompt patients daily to report whether or not they took their blood pressure medication. in addition, participants will be provided with a wrist-worn sensor and instructed to wear it at night to track their sleep activity.
Data on sleep activity will be available to patients through a separate patient-facing app accessible on their smartphone.
Weekly financial incentives for measuring their blood pressure as instructed (up to $25/week: $5/day for up to 5 days/week)
|
|
Active Comparator: Delayed Financial Incentives for BP monitoring
|
Participants will be given a home blood pressure machine and instructed to take their blood pressure twice/day (once in the morning and once at night) for the duration of the 2-month study.
Blood pressure values will be immediately available in their patient-facing portal accessible via smartphone app, and patients will receive weekly feedback reports on their adherence to the home blood pressure monitoring protocol.
Patients' blood pressure values will also be accessible to their clinical care team via an administrator portal, which will alert clinicians of any values above or below pre-specified clinical thresholds.
As part of self-monitoring of hypertension-related factors, the blood pressure monitoring patient-facing app will also prompt patients daily to report whether or not they took their blood pressure medication. in addition, participants will be provided with a wrist-worn sensor and instructed to wear it at night to track their sleep activity.
Data on sleep activity will be available to patients through a separate patient-facing app accessible on their smartphone.
Financial incentives for measuring their blood pressure as instructed in one payment at the end of the study (up to $25/week: $5/day for up to 5 days/week)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Between-group difference in weekly adherence to blood pressure monitoring
Time Frame: 8 weeks
|
Weekly adherence to blood pressure monitoring will be defined as the number of days that the participant used the home blood pressure monitor at least once, captured in the blood pressure monitoring app usage data.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Between-group mean difference in change in systolic blood pressure
Time Frame: 8 weeks
|
Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines.
|
8 weeks
|
|
Between-group mean difference in change in diastolic blood pressure
Time Frame: 8 weeks
|
Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines.
|
8 weeks
|
|
Between-group difference in the proportion with blood pressure control (<130/80 mm Hg)
Time Frame: 8 weeks
|
Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines.
Blood pressure control will be defined as systolic <130 mm Hg and diastolic <80 mm Hg.
|
8 weeks
|
|
Between-group difference in the proportion with systolic blood pressure control (<130 mm Hg)
Time Frame: 8 weeks
|
Blood pressure will be measured at baseline and 8-week follow-up by a certified Clinical Research Coordinator using the average of three seated blood pressure measurements and in accordance with American Heart Association (AHA) guidelines.
Systolic blood pressure control will be defined as systolic <130 mm Hg.
|
8 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patient approached for recruitment
Time Frame: 3 months
|
Number of patients with reachable phone numbers or approached in clinic
|
3 months
|
|
Number of patients assessed for eligibility
Time Frame: 3 months
|
Number of patients who begin eligibility screener
|
3 months
|
|
Number of patients enrolled
Time Frame: 3 months
|
Number of patients who consent and are randomized
|
3 months
|
|
Number of patients who receive intended treatment
Time Frame: 2 months
|
Proportion of total possible financial incentive received
|
2 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Marie Krousel-Wood, MD, MSPH, Tulane University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Behavior
- Treatment Adherence and Compliance
- Hypertension
- Health Behavior
- Patient Participation
- Patient Compliance
- Patient Acceptance of Health Care
- Health Services Administration
- Delivery of Health Care
- Telemedicine
- Patient Care Management
- Remote Patient Monitoring
Other Study ID Numbers
- 2020-1600-BENH
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
Abant Izzet Baysal UniversityNot yet recruitingPRIMARY HYPERTENSIONTurkey (Türkiye)
-
SingHealth PolyclinicsNanyang PolytechnicEnrolling by invitationHypertension,EssentialSingapore
-
Hacettepe UniversityBozok UniversityCompletedHypertension | Arterial Hypertension | Systemic HypertensionTurkey (Türkiye)
-
BackBeat Medical IncNot yet recruitingHypertension, Systolic | Hypertension (HTN) | Heart Failure With Preserved Ejection Fraction (HFpEFGeorgia
-
Xuanwu Hospital, BeijingNot yet recruiting
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Not yet recruiting
-
Instituto de Cardiologia do Rio Grande do SulCompletedHypertension (HTN) | Hypertension ArterialBrazil
Clinical Trials on Remote Patient Monitoring
-
Northwestern UniversityOmron Healthcare Co., Ltd.Completed
-
University of Mississippi Medical CenterHealth Resources and Services Administration (HRSA)Completed
-
University of British ColumbiaCompleted
-
Columbia UniversityNew York Presbyterian Hospital; Philips HealthcareCompleted
-
Tracy Jalbuena MDHealth Resources and Services Administration (HRSA); MaineHealthWithdrawnDiabetes Mellitus, Type 2United States
-
Charite University, Berlin, GermanyCompletedRemote Patient Monitoring on Intensive Care UnitGermany
-
University of California, DavisCompletedType 1 DiabetesUnited States
-
Massachusetts General HospitalWithdrawnGastrointestinal Cancer
-
Centre Hospitalier de BlignyCureety; Exystat; Pharmaspecific; ProPensCompleted
-
University of ChicagoActive, not recruiting